CClinicalTrials.gg
Active, not recruitingNCT06267430LbHUpdated Jul 23, 2026

Learning by Heart: The Effectiveness of an EF Training Program for Pre-schoolers With a Severe CHD

An interventional study of Kleuter Extra training program in Congenital Heart Disease, Executive Dysfunction and Attention Disorder, sponsored by Erasmus Medical Center. Active, not recruiting at 3 sites in Netherlands. Open to participants aged 4 Years to 7 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Erasmus Medical Center · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
4 Years to 7 Years
Sex
All
01

Study summary

Advances in prenatal and neonatal care have improved outcomes in children with severe congenital heart disease (CHD). With the increase in survival, neurocognitive problems such as executive functioning (EF) impairments have become more apparent in these children. EF problems have cascading negative effects on a child's development. New insights in EF development suggest that in otherwise physically healthy young children, EF can be improved by training. In a pilot study funded by Stichting Hartekind, the investigators studied the feasibility of a personalized EF training program called 'Kleuter Extra' and the results were promising. Therefore, the current study will investigate the effectiveness of this program in 4-6-year-old children with severe CHD. The researchers will also explore interactions between the parent-child relationship and EF development of the child as psychosocial difficulties in these children and their parent(s) and/or caretaker(s) may impact EF-development. If found effective, EF training for children with severe CHD will improve their developmental outcome.

Read the detailed description

Advances in prenatal and neonatal care have improved outcome in children with severe congenital heart disease (CHD), with survival rates up to 90%. With the increase in survival, neurocognitive problems and psychological maladjustment have become more apparent in these children, such as impairments in their executive functioning. Executive functioning (EF) is an umbrella-term for several higher-order cognitive processes crucial for self-regulated and goal directed behaviour. Frequently postulated components of EF are inhibition, including motor inhibition, and attention, working memory, and cognitive flexibility. Early EF problems often result in emotion regulation difficulties, behavioural problems, social problems, and learning problems, which can lead to diminished functioning in social domains and lower achievement levels in education and employment status. Children with CHD might be rendered even more vulnerable for EF-problems since EF development is embedded within the social context of a child. There is an increasing understanding of how naturally distressing the CHD diagnosis and treatment can be for parents, which can impair the interactions with their child and in turn might negatively impact the child's EF development. Looking at the reciprocal nature of relationships, the child's illness and/or emotional and behavioural problems that may be associated with EF difficulties might negatively impact the parent-child relationship, parenting behaviour and parental wellbeing. However, these relations are poorly understood, especially regarding fathers. A greater understanding of the interplay between biological and psychosocial factors on EF-development is needed to promote optimal developmental outcomes for these vulnerable children.

New insights suggest that EF can be improved by training. Due to neural plasticity, the window for effective training seems to be between the ages of two and six years. After this time frame, improvements in EF may not retain after training or not generalize to off-task functions. Current EF training programs are not personalised ('adaptive') but offer the same program regardless of the specific child's EF dysfunctions, which may explain their limited effects. There is presently no effective EF training program for children with CHD.

In a pilot study funded by Stichting Hartekind, the researchers investigated the feasibility of a personalised EF training program called 'KleuterExtra' in 4-6 year old children with severe CHD. Within a week, 31 children were (self-) referred for the study, indicating a great clinical need. Directly after training, children showed clinically relevant improvement on the specific EFs targeted in training, with Cohen's d effect sizes ranging from 0.19 to 2.41 (>1.00 on 5 out of 9 tasks). Improvement was also found in untrained EFs and tasks that combined multiple EFs, indicating a generalization effect. Parents and teachers spontaneously reported positive results in daily life. Based on these promising results, the investigators designed the current randomized, controlled study to test the effectiveness of this training program in pre-schoolers with severe CHD.

Given the above, the investigators designed this study to investigate the effectiveness of a tailored EF training program for preschoolers with severe CHD. Secondary aim was to explore interactions between the parent-child relationship and the EF development of the child. If found effective, EF training for children with severe CHD will improve their developmental outcome.

02

Conditions studied

  • Congenital Heart Disease
  • Executive Dysfunction
  • Attention Disorder

Keywords

  • Congenital heart disease
  • Preschooler
  • Executive functions
  • Training
03

In context

Heart Defects, Congenital

1,010 studies on the registry are indexed under Heart Defects, Congenital; 260 are open to participants now.

This study's planned enrollment of 108 is above the median of 60 across 525 interventional studies indexed under Heart Defects, Congenital.

Browse Heart Defects, Congenital studies →

Lead sponsor

Erasmus Medical Center is the lead sponsor of 466 studies on the registry; 179 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

In order to be eligible to participate in this study, a child must meet all of the following criteria:

  • Aged 4.0 - 6.0 years upon inclusion OR aged 6.0-7.0 years who are still in kindergarten (group 1 \& 2 of the Dutch school system)
  • Required CHD surgery in the first six months of life (with or without ECMO) or a cyanotic CHD that required surgery in the first 12 months of life
  • IQ estimated > 55 (no moderate to severe intellectual disability)
  • Diminished EF based on a below average score on any of the subtests of the 'KleuterExtra' test battery (≤ 21 percentile) at t = 0
  • Sufficient comprehension of the Dutch language by the child to be able to participate in the EF test battery and the EF training program. In order to be eligible to participate in this study, the parent(s) must meet the following criteria:
  • Sufficient comprehension of the Dutch language to understand the study information and to be able to fill out the Dutch questionnaires.

Exclusion Criteria:

  • Children receiving targeted EF support at school upon inclusion.
  • Children with severe brain damage (estimated IQ \< 55)
  • Genetic syndromes known to directly affect cognitive performance (e.g. Down syndrome)
  • Children with severe psychiatric disorders upon inclusion that require treatment first, such as a posttraumatic stress disorder, separation anxiety disorder, or reactive attachment disorder.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Investigator)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Intervention group

    The participants allocated to the intervention group will receive the personalised training program 'KleuterExtra', developed by dr. Lex Wijnroks from Utrecht University. All parents will receive the book 'Speels Brein' ('Playful Brain') and an age-appropriate addition for preschoolers to this book.

    Behavioral: Kleuter Extra training program

  • No intervention
    Control group

    As described, the parents of the control group will also receive the book 'Speels Brein' ('Playful Brain') and the age-appropriate addition for preschoolers to this book.

Interventions

  • BehavioralKleuter Extra training program

    The intervention was described in the included arm/group explanation.

06

What researchers measure

Primary outcomes

  1. Kleuter Extra test battery

    The primary endpoint is a single composite score on the 'Kleuter Extra' EF test battery. This composite score will be statistically derived from the individual test results of the test battery. Therefore, the minimum and maximum values cannot be provided at this point, nor whether a higher score means a better or worse outcome.

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

Secondary outcomes

  1. EF functioning

    Single test scores from the ''Kleuter Extra'' EF test battery: * subtest 'Pencil Tap'. Scores range from 0 to 100. * subtest 'Go/No go animals'. Scores range from 0 to 60. * subtest 'Statue task'. Scores range from 0 to 30. * subtest 'Search task'. Scores range from 0 to 35. * subtest 'Sustained attention'. Scores range from 0 to 30. * subtest 'Corsi blocks'. Scores range from 0 to 26. * subtest 'Dots'. Scores range from 0 to 37. * subtest 'Numbers'. Scores range from 0 to 54. * subtest 'Three is Correct'. Scores range from 0 to 78. * subtest 'Head-Shoulders-Knees-Toes'. Scores range from 0 to 52. A higher score indicates a better outcome for all subtests, except the 'Pencil Tap' task. The scores are converted into percentiles ranging from the lowest percentile rank (0-3) to the highest percentile rank (\>75) with a higher score indicating a better outcome.

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  2. Information processing

    Cognitive Proficiency Index of the WPPSI-IV-NL. This index score is based on the test results of the following subtests: * subtest 'Picture Memory' * subtest 'Zoo Locations' * subtest 'Bug Search' * subtest 'Cancellation' * subtest 'Animal Coding'. The scale scores range from 1 to 19 and a higher score indicates a better outcome.

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  3. Executive functioning in daily life - completed by the parent(s)

    Behavior Rating Inventory of Executive Function - Preschool Version questionnaire (BRIEF-P): t-scores range from 20-80, higher scores indicate worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  4. Behavioral and emotional difficulties of the child - completed by the parent(s)

    Child Behavioral Checklist questionnaire 1,5 - 5 years old (CBCL): t-scores range from 50-100, higher scores indicate worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  5. Quality of the child's life - completed by the parent(s)

    Preschool Children Quality of Life questionnaire (TAPQOL): t-scores range from 0 - 100, higher score indicates better outcome.

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  6. Emotional distress parent - completed by the parent(s)

    Depression, Anxiety, Stress Scale (DASS-21): scores range from 0-63, higher score indicates worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  7. Parental trauma

    PCL-5 questionnaire ('PCL-5' is the title, scores range from 0-80, higher score indicates worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  8. Parenting behavior and quality parent-child relationship - completed by the parent(s)

    Parenting Behavior questionnaire (PABI): scores range from 0-525, a higher score can mean a better or worse outcome depending on the specific scale.

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  9. Child demographics teacher's perspective

    Additional support in school, type, being held back a year (qualitative data, designed by the study group)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  10. Behavioral and emotional difficulties teacher's perspective

    Teacher's Report Form questionnaire (TRF): t-scores range from 50-100, higher scores indicate worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

  11. Executive functioning child in daily life teacher's perspective

    Behavior Rating Inventory of Executive Function questionnaire - teachers (BRIEF); t-scores range from 20-80, higher scores indicate worse outcome)

    Time frame: 9 weeks after baseline. Additional measures at 6 months and 12 months after baseline.

07

Study locations

3 sites
  • University Medical Center - Beatrix children&#39;s hospital Groningen
    Groningen, Provincie Groningen 9713GZ, Netherlands
  • Erasmus Medical Center Sophia Children&#39;s Hospital
    Rotterdam, Rotterdam 3015CN, Netherlands
  • University Medical Center - Wilhelmina children's hospital Utrecht
    Utrecht, Utrecht 3584EA, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06267430
Lead sponsor
Erasmus Medical Center
Responsible party
Andre Rietman (Doctor, Neuropsychologist, Erasmus Medical Center) — Principal investigator
First posted
Feb 20, 2024
Start date
May 1, 2024
Primary completion
Oct 29, 2025
Completion
Oct 31, 2026 (estimated)
Last update
Jul 23, 2026

Study contacts

André Rietman
principal investigator · Erasmus Medical Center
Renske Schappin
principal investigator · Erasmus Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion